MX2013005507A - Methods of treating tumors. - Google Patents

Methods of treating tumors.

Info

Publication number
MX2013005507A
MX2013005507A MX2013005507A MX2013005507A MX2013005507A MX 2013005507 A MX2013005507 A MX 2013005507A MX 2013005507 A MX2013005507 A MX 2013005507A MX 2013005507 A MX2013005507 A MX 2013005507A MX 2013005507 A MX2013005507 A MX 2013005507A
Authority
MX
Mexico
Prior art keywords
treating tumors
methods
pak1
hyper
administering
Prior art date
Application number
MX2013005507A
Other languages
Spanish (es)
Inventor
Klaus P Hoeflich
Hartmut Koeppen
Christy C Ong
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013005507A publication Critical patent/MX2013005507A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to a method of treating tumors wherein PAK1 is over- expressed or amplified by co-administering a PAK1 inhibitor and a second anti-hyper- proliferative agent.
MX2013005507A 2010-11-17 2011-11-14 Methods of treating tumors. MX2013005507A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41467110P 2010-11-17 2010-11-17
US201161523062P 2011-08-12 2011-08-12
PCT/EP2011/070008 WO2012065935A1 (en) 2010-11-17 2011-11-14 Methods of treating tumors

Publications (1)

Publication Number Publication Date
MX2013005507A true MX2013005507A (en) 2013-07-17

Family

ID=44993549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005507A MX2013005507A (en) 2010-11-17 2011-11-14 Methods of treating tumors.

Country Status (9)

Country Link
EP (1) EP2640369A1 (en)
JP (1) JP2013542965A (en)
KR (1) KR20130121122A (en)
CN (1) CN103298461A (en)
BR (1) BR112013012175A2 (en)
CA (1) CA2817133A1 (en)
MX (1) MX2013005507A (en)
RU (1) RU2013126036A (en)
WO (1) WO2012065935A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916574B2 (en) 2009-09-28 2014-12-23 Qilu Pharmaceutical Co., Ltd. 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors
US9546173B2 (en) 2012-09-19 2017-01-17 Novartis Ag Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors
RU2015138576A (en) * 2013-03-14 2017-04-19 Дженентек, Инк. COMBINATIONS OF THE COMBINATION OF THE MEK INHIBITOR WITH THE CONNECTION OF THE HER3 / EGFR INHIBITOR AND METHODS OF APPLICATION
EP3416623B1 (en) 2016-02-15 2021-08-11 University of Georgia Research Foundation, Inc. Ipa-3-loaded liposomes and methods of use thereof
JP6900406B2 (en) * 2016-06-16 2021-07-07 ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド Dihydropyrazoloazepine compounds as Akt inhibitors
US20220218715A1 (en) * 2019-05-22 2022-07-14 Voronoi Co., Ltd. Novel use of pyrrolo-pyridine derivative compound for prevention and/or treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005323797B2 (en) 2005-01-10 2009-07-09 Pfizer Inc. Pyrrolopyrazoles, potent kinase inhibitors
RU2007140734A (en) 2005-04-06 2009-05-20 Астразенека Аб (Se) SUBSTITUTED HETEROCYCLES AND THEIR APPLICATION AS CHKI, PDKI AND PAK INHIBITORS
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
PT1979356E (en) 2005-12-21 2013-11-21 Pfizer Prod Inc Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
CA2691251A1 (en) * 2007-06-19 2008-12-24 Yoshikazu Ohta Preventive/remedy for cancer
US7998688B2 (en) * 2008-03-07 2011-08-16 OSI Pharmaceuticals, LLC Inhibition of EMT induction in tumor cells by anti-cancer agents
US8674095B2 (en) 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions

Also Published As

Publication number Publication date
CN103298461A (en) 2013-09-11
KR20130121122A (en) 2013-11-05
BR112013012175A2 (en) 2019-09-24
RU2013126036A (en) 2014-12-27
WO2012065935A1 (en) 2012-05-24
CA2817133A1 (en) 2012-05-24
JP2013542965A (en) 2013-11-28
EP2640369A1 (en) 2013-09-25

Similar Documents

Publication Publication Date Title
EA201200559A1 (en) METHODS OF APPOINTMENT PYRPHENIDONE THERAPY
WO2012142498A3 (en) Mif inhibitors and their uses
PH12015502059A1 (en) Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
ECSP13012394A (en) NEW FORMS OF MODIFIED RELEASE DOSAGE OF AN XANTINA OXIDORREDUCTASA INHIBITOR OR XANTINA OXIDASA INHIBITORS
MX2017003358A (en) Novel compounds.
SG190819A1 (en) Nampt and rock inhibitors
MX352926B (en) Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases.
WO2013182912A3 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
IN2012DN03883A (en)
EP2575884A4 (en) Uses and compositions for treatment of hidradenitis suppurativa (hs)
GB201103062D0 (en) Method
MX2013005507A (en) Methods of treating tumors.
EA201490944A1 (en) DOUBLE MET AND VEGF INHIBITOR FOR CANCER TREATMENT
MX2015006478A (en) Glutamase inhibitors and method of use.
MX2014006241A (en) Methods of treatment using an antibody against interferon gamma.
GEP20156341B (en) Anticoagulant antidotes
WO2014055543A3 (en) Biomarkers and methods to predict response to inhibitors and uses thereof
MX2014013752A (en) Nampt inhibitors.
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
NZ603773A (en) Asparaginase from basidiomycetes
MX348311B (en) Nampt inhibitors.
EA201300688A1 (en) NEW FORM OF INTRODUCTION ENECHALINASE INHIBITOR
MX2013011932A (en) Parp inhibitors for the treatment of cipn.
EA201590744A1 (en) TORRING OF TOR CANCER BY KINASE INHIBITORS
IN2014DN08385A (en)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal